Androgen deprivation therapy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Differences between a healthy prostate and a prostate with a tumour

Androgen deprivation therapy (ADT), also called androgen suppression therapy, is a treatment based on the reduction of androgen hormones, which stimulate prostate cancer cells to grow.[1] The therapy can also eliminate cancer cells by inducing androgen deprivation-induced senescence.[2] Lowering androgen levels or stopping them from getting into prostate cancer cells often makes prostate cancer shrink or grow more slowly for a time. However, this treatment needs to be combined with radiation therapy (RT)[3] because ADT itself does not eradicate the cancer; it just decreases its aggressiveness.[4]

Types[edit]

Method based on surgery[edit]

It consists of removing the testicles, the organ where androgens are synthesized, of the cancer sufferers. It is the most radical treatment for ending up the production of androgens. Moreover it is the easiest and least expensive one. The main disadvantage is that surgical castration is a permanent method.

Methods based on drugs[edit]

Testosterone synthesizing process

The synthesis of testosterone is mediated by a chain of processes that start in our brain. When our body detects a low level of testosterone, the hypothalamus starts to produce LHRH, an hormone which, once is received by the pituitary gland activates the synthesis of LH (Luteinizing hormone). LH travels to the testicles where induces the formation of testosterone.[5] There are two methods of androgen deprivation therapy based on drugs. One works preventing the pituitary gland from releasing LH and the other one blocks the body’s ability to use androgens.

  • Chemical castration
There are two different medicines, LHRH agonists and antagonists, which both lower the amount of testosterone made by the testicles. They work inhibiting the formation of LH in the pituitary gland. The LHRH agonists produce a sudden increase on levels of testosterone followed by a huge falling, process called flare, whereas LHRH antagonists decrease directly the amount of testosterone. Some of the most common LHRH agonist and antagonist active substances are leuprolide, goserelin, triptorelin, histrelin and degarelix.
These drugs are injected under the skin achieving the same result as surgical castration. Although it is much more expensive, men tend to choose this option as they are usually reluctant to have their testicles cut.
  • Anti-androgen
Adrenal glands were discovered as another center of androgen production even after a castration process. So it was developed a complementary treatment that uses anti-androgens which block the body’s ability to use any androgens. The prostate cells have an androgen’s receptor inside. This complex of androgen and receptor promotes the cellular division. This is a problem when it occurs in a cancer cell. Anti-androgen molecules can enter cells and prevent the binding of testosterone to the receptor proteins, due to a higher affinity of this receptors to the drug instead of the androgen.
The main anti-androgens molecules are flutamide, bicalutamide and nilutamide which are all taken as pills.

Effects on men's sexuality[edit]

Normal male sexuality seems to depend upon very specific and complicated hormonal patterns that are not completely understood.[6] One study suggests that ADT can alter the hormonal balance necessary for male sexual activity. As men age, testosterone levels decrease by about 1% a year after age 30; however, it is important to determine whether low testosterone is due to normal aging, or to a disease, such as hypogonadism.[7] Testosterone plays a significant role in sexual functioning; therefore, naturally declining levels of testosterone can lead to reduction in normal sexual functioning. Further decreases in serum testosterone can have a negative impact on normal sexual function, leading to a decline in quality of life.[8]

Erectile dysfunction is not uncommon after radical prostatectomy and men who undergo ADT in addition to this are likely to show further decline in their ability to engage in penetrative intercourse, as well as their desire to do so.[7] A study looking at the differences of using GnRH-A (and androgen suppressant) or an orchiectomy report differences in sexual interest, the experience of erections, and the prevalence of participating in sexual activity. Men reporting no sexual interest increased from 27.6% to 63.6% after orchiectomy, and from 31.7% to 58.0% after GnRH-A; men who experienced no erections increased from 35.0% to 78.6%; and men who did not report engaging in sexual activity increased from 47.9% to 82.8% after orchiectomy and 45.0% to 80.2%.[8] This study suggests that the GnRH-A and orchiectomy had similar effects on sexual functioning. A vicious cycle whereby lowering testosterone levels leads to decreased sexual activity, which in turn cause both free and total testosterone levels to decline even further.[6] This demonstrates the importance of androgens for maintaining sexual structures and functions.[6]

Adverse effects[edit]

Due to the changes in the levels of sexual hormones (testosterone); Orchiectomy, LHRH analogs and LHRH antagonists can all cause similar side effects:[9]

  1. Hot flushes, which can go away with time
  2. Impotence
  3. Loss of sexual desire
  4. Anemia
  5. Osteoporosis
  6. Decreased mental sharpness
  7. Loss of muscle mass
  8. Weight gain
  9. Fatigue
  10. Increased cholesterol
  11. Depression
  12. Breast tenderness and growth of breast tissue

Because of all of these side effects, androgen deprivation therapy is only applied in advanced prostate cancers and high-risk localized disease.[10]

Further reading[edit]

References[edit]

  1. ^ Perlmutter and Lepor (2007). "Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer". Rev Urol. 9 Suppl 1: S3–8. PMC 1831539. PMID 17387371. 
  2. ^ Burton, Dominick G. A.; Giribaldi, Maria G.; Munoz, Anisleidys; Halvorsen, Katherine; Patel, Asmita; Jorda, Merce; Perez-Stable, Carlos; Rai, Priyamvada; Agoulnik, Irina U. (27 June 2013). "Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells". In Agoulnik, Irina U. PLoS ONE 8 (6): e68003. doi:10.1371/journal.pone.0068003. PMC 3695935. PMID 23840802. 
  3. ^ "Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial". The Lancet 378 (9809): S2104–2111. 2011. doi:10.1016/s0140-6736(11)61095-7. "Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3"
  4. ^ Science Daily
  5. ^ Prostate Cancer Guide
  6. ^ a b c Mazzola, C.R., & Mulhall, J.P. (2012). Impact of androgen deprivation therapy on sexual function. Asian Journal of Andrology, 14, 198-203. doi:10.1038/aja.2011.106
  7. ^ a b (2012). Testosterone therapy: Key to male vitality? Retrieved from: http://www.mayoclinic.com/health/testosterone-therapy/MC00030
  8. ^ a b Sharifi, N., Gulley, J.L., & Dahut, W.L. (2005). Androgen deprivation therapy for prostate cancer. The Journal of the American Medical Association, 294(2), 238-244. doi:10.1001/jama.294.2.238
  9. ^ Medline Abstract
  10. ^ The Journal of American Medical Association (JAMA)